
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at 2 drugs called bezafibrate and medroxyprogesterone to treat several different cancers. Bezafibrate is a drug for lowering cholesterol and medroxyprogesterone is a steroid. The trial is testing this combination on
Doctors usually treat these with chemotherapy and occasionally radiotherapy. But sometimes the cancer starts to grow again. When this happens it is often more difficult to treat.
Doctors know from previous research that bezafibrate and medroxyprogesterone may stop cancer cells growing.
The aims of this trial are to find out
You may be able to enter this trial if you
You cannot enter this trial if you
About 60 people will take part in this study from the West Midlands area.
Everyone taking part will take bezafibrate and medroxyprogesterone tablets daily. You continue to take the tablets for as long as your doctor thinks they are helping you.
The trial team will ask you to fill out a questionnaire before you start treatment and twice during it.
This questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
If you agree to take part in this study, the researchers will take extra blood and urine samples. They will use these samples to look at why the treatment may work better for some people than others.
You will see the doctors and have some tests before you start treatment. The tests include
You will see the doctors and have blood and urine tests frequently for the first 18 weeks of treatment.
After 18 weeks you will see the doctors and have a bone marrow test (if you had one before treatment). If you have non Hodgkin’s lymphoma you will have a CT scan.
You continue to take the tablets if they are helping you. Your doctor will talk to you about how often you need to visit the hospital.
When you stop treatment you will continue to see your cancer doctor as usual, but there will be no more hospital visits as part of the trial.
The most common side effects of bezafibrate and medroxyprogesterone are
Women may have breast tenderness and abnormal vaginal bleeding.
There is more information about medroxyprogesterone in our cancer drugs section.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Mark Drayson
Cancer Research UK Clinical Trials Unit
Birmingham
Experimental Cancer Medicine Centre (ECMC)
Queen Elizabeth Hospital Birmingham
University of Birmingham
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.